Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa

Epidermylosis Bullosa Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00231517
• Other study ID #: 01MH17
• Status: Completed
• Phase: Phase 4
• First received: October 3, 2005
• Last updated: October 11, 2006

Study information

• Verified date: October 2005
• Source: Institute of Child Health
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Randomised Double blind placebo controlled cross over design study of the efficacy of morphine for inflammatory pain in children with Epidermolysis Bullosa

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 4 Years to 18 Years

Eligibility

Inclusion Criteria:

• children under 18 years epidermolysis wounds requiring dressing changes

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Epidermylosis Bullosa

Intervention

Drug:
• topical opiod

• morphine sulphate in intrasite gel

Locations

Country	Name	City	State
United Kingdom	Great Ormond Street Hospital and the Institute of Child health	London

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Child Health

Country where clinical trial is conducted

United Kingdom,